

# Vancomycin resistance among methicillin resistant *Staphylococcus Aureus* isolates from general hospitals

Rashad A. Abdul-Hameed M.Sc\*, Nedhal S. Ayoub\* M.Sc.

## ABSTRACT

**Background:** Multidrug resistant methicillin-resistant *Staphylococcus aureus* (MRSA) is a major cause of nosocomial and community acquired infections. The glycopeptides vancomycin has been proposed as the drug of choice for treating such infections; this lead to the emergence of vancomycin intermediate sensitive *S. aureus* (VISA) and vancomycin resistant *S. aureus* (VRSA).

**Objectives:** To identify the vancomycin resistance both phenotypically and genotypically among MRSA isolates from different hospitals and to determine the sensitivity of these isolates to different antimicrobial agents.

**Methods:** A total of 204 *S. aureus* isolates were obtained randomly from various clinical specimens including (wound swab, burn swab, ear swab, urine, sputum, blood and other body fluids) from different inpatient and outpatient who were attending different hospitals in Baghdad. The susceptibility pattern of the *S. aureus* isolates to different antibiotics was determined by disk diffusion method and vancomycin minimum inhibitory concentration (MIC) for MRSA isolates were determined using broth dilution method following clinical laboratory standard institution (CLSI) guidelines. *Van A* gene was amplified by PCR using standard primers.

**Results:** All VRSA isolates were MRSA. Twelve VRSA isolates were positive for *van A* gene, while the remaining ten isolates were negative. All VRSA had a vancomycin MIC of 16µg/ml or more. In the present study, VRSA showed resistance to a wide range of antimicrobial agents (ampicillin, cephalothin, cefoxitin, erythromycin, gentamicin, oxacillin, penicillin, rifampin, tetracycline and trimethoprim).

**Conclusions:** There were high incidences of resistance to the commonly used antibiotics among VRSA isolates compared to VISA and VSSA. Further molecular studies such as PCR technique to identify genes rather than *van A* (e.g. *van HAX* analogue) might be suitable to predict VRSA lacking the *van A* gene.

**Keywords:** *Staphylococcus aureus*, MRSA, VRSA, VISA, *van A* gene.

*Al-Kindy College Medical Journal 2015: Vol. 11 No. 1*  
*Page: 6-9*

\*Dept. of microbiology, College of medicine, University of Baghdad.  
Received 4<sup>th</sup> Nov 2013, accepted in final 30<sup>th</sup> Dec 2013  
Corresponding to Prof Rashad Ayad Abdul -Hameed, e. mail  
Rashad\_ayad@yahoo.com , mobile: 07901283279

Multidrug resistant *S. aureus* is a common cause of nosocomial infection. Measures to control *S. aureus* infections are challenged by a large and continuing increase in the prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) worldwide, the spread of highly virulent community-associated MRSA and the emergence of *S. aureus* with reduced susceptibility to vancomycin and other glycopeptides<sup>1</sup>.

The condition has been further worsened by the emergence of vancomycin intermediate sensitive *S. aureus* (VISA) and Vancomycin resistant *S. aureus* (VRSA). Strains with upper levels of Minimum inhibitory concentration (MIC) of vancomycin induce high morbidity and mortality rates compared to those which have lower levels of vancomycin MIC<sup>2</sup>. As per latest clinical and laboratory standard institute guidelines staphylococci with MIC of vancomycin  $\leq 2$  µg/ml is susceptible (VSSA), while for which MIC is 4-8 µg/ml are intermediate (VISA) and those with MIC  $\geq 16$  µg/ml are resistant (VRSA)<sup>3</sup>. The glycopeptide vancomycin was considered to be the best alternative for the treatment of multidrug resistant MRSA. However, there are increasing numbers of reports indicating the emergence of VRSA strains exhibiting two different resistance mechanisms. Initially VISA noted in Japan in 1996 and subsequently in the United States in 1997, was believed to be due to the thickened cell wall<sup>4</sup>, where many vancomycin molecules were trapped within the cell wall. The trapped molecules

clog the peptidoglycan meshwork and finally form a physical barrier towards further incoming vancomycin molecules<sup>5</sup>. The second, noted in the United States in 2002 among *S. aureus*, was identical to the mechanism seen in vancomycin-resistant Enterococcus. Vancomycin-resistant *Enterococcus faecium* harbours the *van A* operon, which contains five genes, *VanS*, *-R*, *-H*, *-A* and *-X*<sup>4</sup>.

The genetic exchange of antimicrobial resistance determinants among enterococci and staphylococci is well documented. The resistance genes are typically found on conjugative plasmids or transposons<sup>6</sup>. However, Tiwari and Sen have reported a VRSA which is *van* gene negative<sup>7</sup>. Subsequent isolation of VISA and VRSA isolates from other countries including Brazil, France, United Kingdom, Germany<sup>4</sup>, India<sup>8</sup>, and Belgium<sup>9</sup> has confirmed that the emergence of these strains is a global issue.

The aim of the present study is to identify the vancomycin resistance both phenotypically and genotypically among MRSA isolates from different hospitals and to determine the sensitivity of these isolates to different antimicrobial agents.

**Methods.** Bacterial isolates; A total of 204 *S. aureus* isolates were obtained randomly from various clinical specimens including (wound swab, burn swab, ear swab, urine, sputum, blood and other body fluids) from different inpatient and outpatient who were attending Baghdad teaching hospital, burns hospital, Al-Karama hospital, and Al-Imam Ali hospital, for the period from November 2012 to May 2013

Antibiotic susceptibility testing: The antibiotic resistance profile was determined by the disc agar diffusion method using different antimicrobial agents; ampicillin (10µg), cephalothin (30µg), cefoxitin (30µg), erythromycin (15µg), gentamicin (10µg), oxacillin (1µg), penicillin (10 units), rifampin (5µg), tetracycline (30µg), trimethoprim (5µg), vancomycin (30µg). The procedure which was accepted by the National Committee for Clinical Laboratory Standard (NCCLS) was employed as described by Bauer et al<sup>10</sup>.

Determination of minimal inhibitory concentration (MIC) of vancomycin was determined by broth dilution method. Gradient tubes of nutrient broth were prepared with vancomycin (2 - 32 µg / ml) and inoculated with bacterial suspension of moderate turbidity (compared to that of Mac Farland 0.5 barium sulfate standard). The broth was incubated at 37°C for about 24 hours. The turbidity of each tube was compared with the turbidity of control tube; the MIC is defined as the lowest concentration of antibiotic at which there is no visible growth of organism<sup>11</sup>.

PCR amplification for *van A* gene: *Van A* gene was detected in VRSA strains by conventional Polymerase chain reaction (PCR) technique using primers of *van A* gene with the following sequence<sup>4</sup>:

Forward: 5'-ATGAATAGAATAAAAGTTGC-3' and Reverse: 5'- TCACCCCTTTAACGCTAATA-3'.

The amplification conditions were initial denaturation at 95°C for 3min, followed by 35 cycles of denaturation at 95 °C for 15 seconds; primer annealing at 55 °C for 15 seconds; extension at 72 °C for 15 seconds and one cycle of final extension at 72 °C for 5 minutes, then cooled at 4 °C.

The collected data were analyzed statistically using Chi-square test to find significant difference between 2 variables. P value less than 0.05 is considered as significant. Statistical analyses were performed using MINITAB (12) and SPSS (Statistical Package for social Sciences) version 17.0 computer software<sup>13</sup>.

**Results.** Among the 204 isolates of *S.aureus*, 72 were identified as MRSA by disc diffusion method, 22 (30.5%) of these MRSA isolates were identified as VRSA and 12(16.7%) were VISA and the remaining 38(52.8%) of the isolates were VSSA by determination of MIC, table 1. There were no significant differences (p =0.466) between the number of MRSA (72 out of 204 *S.aureus* isolates) and VRSA (22 out of 72 MRSA) isolates, while the differences between the number of MRSA and each of VISA (12 out of 72 MRSA) and VSSA (38 out of 72 MRSA) were significant (p= 0.003) and (p= 0.009) respectively as shown in table 2.

In the present study, VRSA showed resistance to a wide range of antimicrobial agents. There were no significant differences in resistance rates to all antibiotics used between VRSA and VISA (P > 0.05). There were also highly significant differences in resistance rate to all antibiotics between VRSA and VSSA (p < 0.001). On the other hand, the differences in the resistance rate between VRSA and MRSA were also significant to some antibiotics (P < 0.05 and P < 0.01) and non significant to others (P > 0.05) as shown in table 3.

In PCR method, out of 22 VRSA isolates, 12(55%) showed a band in the region of 1200 bp compared with the ladder used; indicating that these isolates have *van A* gene as shown in figure 1.

**Table 1:** Distribution of 72 MRSA isolates according to the MICs of vancomycin.

MIC ( µg/ml )	No. of strains	%
≥ 16*	22	30.6
8**	5	6.9
4**	7	9.7
2***	38	52.8
Total	72	100

\*MIC ≥16µg/ml = VRSA, \*\*4 -8 µg/ml = VISA, \*\*\* ≤ 2µg/ml =VSSA

**Table 2:** Distribution of *S.aureus* isolates according to its methicillin and vancomycin resistance.

MRSA* No. (%)	VRSA** No. (%)	p value	VISA** No. (%)	p value	VSSA** No. (%)	P value
72(100)	22(30.5)	0.466	12(16.7)	0.003	38(52.8)	0.009

Chi-square: MRSA vs. VRSA, VISA and VSSA. \*MRSA; according to disk diffusion method  
\*\*VRSA, VISA and VSSA according to vancomycin MIC

**Table 3:** Comparison of antimicrobial resistance rates of VRSA, VISA, VSSA and MRSA.

Antibiotics	VRSA strains resistance Total: 22 No. (%)	VISA strains resistance Total: 12 No. (%)	VSSA strains resistance Total: 38 No. (%)	MRSA strains resistance Total: 72 No. (%)
Ampicillin	22(100)	12(100) <sup>NS</sup>	19(50) <sup>***</sup>	55(76.4) <sup>*</sup>
Tetracycline	22(100)	12(100) <sup>NS</sup>	18(47.3) <sup>***</sup>	52(72.2) <sup>**</sup>
Oxacillin	22(100)	12(100) <sup>NS</sup>	2(5.2) <sup>***</sup>	72(100) <sup>NS</sup>
Penicillin	21(95.5)	12(100) <sup>NS</sup>	22(57.8) <sup>**</sup>	68(94.4) <sup>NS</sup>
Cefoxitin	22(100)	12(100) <sup>NS</sup>	1(2.6) <sup>***</sup>	72(100) <sup>NS</sup>
Gentamicin	19(86.4)	10(83.3) <sup>NS</sup>	7(18.4) <sup>***</sup>	36(50) <sup>**</sup>
Cefalothin	17(77.3)	8(66.7) <sup>NS</sup>	4(10.5) <sup>***</sup>	52(72.2) <sup>NS</sup>
Erythromycin	17(77.3)	7(58.3) <sup>NS</sup>	11(28.9) <sup>***</sup>	35 (48.6) <sup>*</sup>
Rifampin	17(77.3)	6(50) <sup>NS</sup>	7(18.4) <sup>***</sup>	30(41.7) <sup>**</sup>
Trimethoprim	16(72.7)	8(66.7) <sup>NS</sup>	6(15.7) <sup>***</sup>	30(41.7) <sup>**</sup>
Vancomycin	6(27.3)	4(33.3) <sup>NS</sup>	0(0) <sup>***</sup>	10(13.9) <sup>**</sup>

Chi- square: VRSA vs. VISA, VSSA and MRSA  
NS: P > 0.05; Not Significant, \*P < 0.05; Significant at 5%,  
\*\*P < 0.01; Significant at 1%, \*\*\*p < 0.001; highly significant




Figure 1: Electrophoresis of PCR product for *van A* gene.

**Discussion.** *Staphylococcus aureus* is one of the important human pathogens that in last decades were a causative agent of community and hospital acquired infections and its resistance increases against  $\beta$ - lactams antibiotics and vancomycin. After the first report of VRSA in Japan in 1997, however, prevalence of VISA and VRSA strains remained low, but in many countries is rising as heterogeneous VISA (hVISA)<sup>14</sup>. In present study; there was no significant difference ( $p = 0.466$ ) between the number of MRSA and VRSA isolates, table 1. Also, the results show that resistance to vancomycin is associated with resistance to methicillin and ceftaxime. This emergence of VRSA may also be due to the selective pressure of vancomycin, a glycopeptides which are currently the main antimicrobial agent available to treat life-threatening infections with MRSA<sup>15</sup>.

The prevalence of the *S.aureus* infections vary from place to place and so also the resistance pattern which depends on the local antibiotics policy, the infection control activities, the time of the study, the number of cases which are studied and the biological characteristics of the *S. aureus* strains<sup>16</sup>.

The MIC values of vancomycin for 72 MRSA isolates, table 2, indicated that different resistance rates were found; this might be related to the level of expression of *van A* gene in these isolates or due to other mechanisms.

Vancomycin resistant *S. aureus* (VRSA) tend to be multidrug resistant against a large number of currently available antimicrobial agents, compromising treatment options and increasing the likelihood of inadequate antimicrobial therapy and increase in morbidity and mortality<sup>17</sup>. In the present study, VRSA showed resistance to a wide range of antimicrobial agents used, table 3. This might be due to lack of sufficient knowledge on the danger of the wrong use of antibiotics, high proximity to a large number of unlicensed drug vendors, high poverty among the people which hinders them from completing the dosage regimen of the antibiotics, widespread and sometimes, the inappropriate use of broad spectrum antibiotics in the medical and the veterinary practice, antibiotic prophylaxis, high number of immune compromised patients, the increased use of invasive procedures and devices and inadequate infection control measures.

The mechanism of vancomycin resistance in VRSA is not well understood. Several genes have been proposed as being involved in certain clinical VRSA strains<sup>18, 19</sup>. The experimental transfer of *van A* gene cluster from *E. faecalis* to *S. aureus* has raised fears about the occurrence of such genetic transfer in clinical isolates of methicillin resistant *S. aureus*<sup>20</sup>. In the current study a PCR amplification for *van A* gene among 22 VRSA isolates; showed that 12(55%) have *van A* gene, the remaining 10(45%) did not have *van A* gene.

In conclusion, results of this study showed that high incidences of resistance to the commonly used antibiotic among VRSA isolates compared to VISA and VSSA. Not all VRSA isolates have *van A* gene this is might be explained by the possibility of the presence of other analogous genes to *van A*.

## References

1. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for *Staphylococcus aureus* clinical isolates from a university hospital during a 5-year period. *Journal of Clinical Microbiology*. 2006;44(11):3883-6.
2. Loomba PS, Taneja J, Mishra B. Methicillin and Vancomycin Resistant *S. aureus* in Hospitalized Patients. *Journal of global infectious diseases*. 2010;2(3):275-83.(IVSL)
3. Wayne P.A. *Performance Standards for Antimicrobial Susceptibility Testing, 17<sup>th</sup> informational supplement, CLSI M100-S17*. 2007; 27(1).
4. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant *Staphylococcus aureus* isolates from intensive care units of tertiary care hospitals in Hyderabad. *Indian J Med Res*. 2011;134(5):704-8.
5. Cui L, Iwamoto A, Lian J-Q, Neoh H-m, Maruyama T, Horikawa Y, et al. Novel Mechanism of Antibiotic Resistance Originating in Vancomycin-Intermediate *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*. 2006;50(2):428-38.(IVSL)
6. Weigel LM, Donlan RM, Shin DH, Jensen B, Clark NC, McDougal LK, et al. High-level vancomycin-resistant *Staphylococcus aureus* isolates associated with a polymicrobial biofilm. *Antimicrobial Agents and Chemotherapy*. 2007;51(1):231-8.(IVSL)
7. Tiwari HK, Sen MR. Emergence of vancomycin resistant *Staphylococcus aureus* (VRSA) from a tertiary care hospital from northern part of India. *BMC Infect Dis*. 2006;6:156.
8. Assadullah S, Kakru DK, Thoker MA, Bhat FA, Hussain N, Shah A. Emergence of low level vancomycin resistance in MRSA. *Indian J Med Microbiol*. 2003;21(3):196-8.
9. Pierard D, Vandenbussche H, Verschraegen I, Lauwers S. [Screening for *Staphylococcus aureus* with a reduced susceptibility to vancomycin in: a Belgian hospital]. *Pathol Biol (Paris)*. 2004;52(8):486-8.(IVSL)
10. Bauer, A. W., Kirby, W. M. M., Sherris, J. C. and Turck, M. Antibiotic susceptibility testing by standardized single disk method. *American J. of Clinic. Pathol.* (1966); 45: 493-496
11. Bailey and Scott's diagnostic microbiology, Mosty. *Antimicrobial susceptibility tests and assays*. 2010;chapter 36, page 389
12. Groebner, David F., Mark L. Berenson, David M. Levine, Timothy C. Krehbiel, and Hang Lau. *Applied management statistics*. Custom ed. Boston, MA: Pearson Custom Publishing/Pearson/Prentice Hall, 2008.
13. Levesque, R. *SPSS Programming and Data Management: A*

- Guide for SPSS and SAS Users**, Fourth Edition (2007), SPSS Inc., Chicago Ill.
14. Sughra Sheikh Muneeri, Haedeh Mobaiyen, Hamid Mirzaie. Study on Vancomycin-Resistant *Staphylococcus aureus* and Identification of VanA Gene in These Strains Isolated from Tabriz Shuhada Hospital Using E-Test and PCR Methods. *Life Science Journal* 2013;10(1) :748-752.
  15. Aligholi M, Emaneini M, Jabalameli F, Shahsavani S, Dabiri H, Sedaght H. Emergence of high-level vancomycin-resistant *Staphylococcus aureus* in the Imam Khomeini Hospital in Tehran. *Med Princ Pract*. 2008;17(5):432-4.
  16. Mallick SK, Basak S. MRSA--too many hurdles to overcome: a study from Central India. *Trop Doct*. 2010;40(2):108-10.
  17. De Lassence A, Hidri N, Timsit JF, Joly-Guillou ML, Thiery G, Boyer A, et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate *Staphylococcus aureus* in an intensive care unit. *Clin Infect Dis*. 2006;42(2):170-8.
  18. Maki H, McCallum N, Bischoff M, Wada A, Berger-Bachi B. tcaA inactivation increases glycopeptide resistance in *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*. 2004;48(6):1953-9.
  19. Jansen A, Turck M, Szekat C, Nagel M, Clever I, Bierbaum G. Role of insertion elements and *yycFG* in the development of decreased susceptibility to vancomycin in *Staphylococcus aureus*. *Int J Med Microbiol* 2007; 297: 205-15.(IVSL)
  20. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *Staphylococcus aureus*. *FEMS Microbiol Lett* 1992; 93: 195-8.